Defining the molecular mechanisms of subtype-specific KCNQ2/3 potassium channel activators
Retigabine is the first approved anti-epileptic drug that acts via activation of voltage-gated potassium channels, targeting KCNQ channels that underlie the neuronal M-current. Retigabine exhibits little specificity between KCNQ2-5, which all contain a Trp residue in the pore domain that is essentia...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2016
|
| Online Access: | http://hdl.handle.net/2429/57894 |